http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101519840-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-755 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-37 |
| filingDate | 2008-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101519840-B1 |
| titleOfInvention | FVIII peptides and uses thereof in the treatment of hemophilia patients |
| abstract | The present invention provides peptides comprising a core residue sequence that can be derived from human FVIII, which is a peptide capable of binding to MHC class II molecules without further antigen treatment. The present invention also relates to the use of such peptides for the prevention or inhibition of the formation of inhibitor antibodies in hemophilia A and / or acquired haemophilia. |
| priorityDate | 2007-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 834.